Abstracts

PREDICTORS OF NEURODEVELOPMENT IN HIV-EXPOSED–UNINFECTED INFANTS

Over one million HIV-exposed uninfected (HEU) children are born annually in sub-Saharan Africa (SSA). Some but not all studies have found increased risk of neurodevelopmental delay, hospitalization, and mortality in HEU children compared to HIV-unexposed uninfected (HUU) children, but predictors of this association remain poorly understood. Mothers living with and without HIV were recruited with…

MITOCHONDRIAL PROTON LEAK IN INFANTS WITH IN UTERO HIV AND ART EXPOSURE IN BOTSWANA

There are limited data on mitochondrial (mt) function in infants HIV-uninfected with in utero HIV and current antiretroviral therapy (ART) exposure (HEU). Infants HEU and infants HIV-unexposed uninfected (HUU) were enrolled in the Tshilo Dikotla study in Botswana from 2016-2019. Mt basal and maximal respiration, ATP production, proton leak, spare respiratory capacity, and non-mt respiration…

HEARING LOSS AND FETAL EXPOSURE TO ANTIRETROVIRAL DRUGS IN HIV-UNINFECTED CHILDREN

Early identification of hearing loss is needed to allow for interventions that can minimize subsequent adverse effects on speech and language development, academic performance, and social interactions. Little is known about hearing sensitivity following fetal exposure to maternal antiretroviral (ARV) drugs among children who remain HIV-uninfected. We included all 5-year-old children who were HIV-exposed but…

NEUTRALIZING ANTIBODY RESPONSE AND TRANSPLACENTAL TRANSFER IN COVID-19 IN PREGNANCY

There are limited data on how COVID-19 disease severity and vaccination throughout different trimesters in pregnancy impact maternal neutralizing antibody responses and transplacental transfer to the neonate at birth. Further characterization of the antibody response of in utero SARS-CoV-2 may inform vaccination schedules in pregnancy in order to optimize maternal and neonatal protection. The COVID-19…

BIRTH OUTCOMES FOLLOWING PRENATAL EXPOSURE TO DOLUTEGRAVIR: THE DOLOMITE-EPPICC STUDY

Dolutegravir (DTG) is recommended and widely used during pregnancy for maternal viral suppression and preventing perinatal transmission of HIV. Our objective is to assess pregnancy and neonatal outcomes including birth defects following prenatal DTG use using real-world European data. Dolomite-EPPICC is a multi-cohort European observational study of DTG use in pregnant women living with HIV…

ADVERSE OUTCOMES IN SUBSEQUENT PREGNANCIES IN THE IMPAACT 2010 TRIAL

Few studies have prospectively captured pregnancy outcomes among women living with HIV (WLHIV) who conceive on antiretroviral treatment (ART). IMPAACT 2010 (VESTED) enrolled 643 WLHIV at 14-28 weeks gestational age in 9 countries. Women were randomized to start ART with dolutegravir (DTG) plus emtricitabine (FTC)/tenofovir alafenamide (TAF); DTG+FTC/tenofovir disoproxil fumarate (TDF); or efavirenz (EFV)/FTC/TDF. Due…

IMPACT OF MATERNAL HIV/HBV COINFECTION ON PREGNANCY AND INFANT OUTCOMES

The impact of maternal HIV/HBV coinfection on the risk of adverse pregnancy and infant outcomes remains understudied. We compared adverse pregnancy and infant outcomes among women living with HIV/HBV versus HIV alone, randomized antepartum to three of antiretroviral (ARV) perinatal transmission regimens in the IMPAACT PROMISE study. ARV-naïve pregnant women with HIV from Africa and…